Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer

Journal of the Pancreas

Volumn 6, Issue 4, 2005, Pages 325-333

  Saif, Muhammad Wasif ^a   Moody, John S ^b   Russo, Suzanne M ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Deoxycytidine; Dihydrouracil dehydrogenase (NADP); Drug toxicity; Fluorouracil; Gastrointestinal hemorrhage; Pancreatic neoplasms; Radiotherapy; Thymidine pPhosphorylase

Indexed keywords

CAPECITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PRODRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL ARTICLE; DRUG DOSE REGIMEN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; MALE; MEDICAL RECORD; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS RESECTION; PATIENT MONITORING; RADIATION DOSE; ADENOCARCINOMA; CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; RADIOTHERAPY;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NEUROENDOCRINE; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PRODRUGS; RADIOTHERAPY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27244454508     PISSN: 15908577     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3:330-8.
2. Lewis NL, Meropol NJ. Oral fluoropyrimidines in cancer treatment. Cancer Invest 2000; 18:747-60.
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluoruracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-81.
4. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55:1091-7.
5. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291-7.
6. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000; 284:3043-5.
7. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radial Oncol Biol Phys 1991, 21; 109-22.
8. Lawrence TS, Davis MA, Tang HY, Maybaum J. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S-phase progression. Int J Radial Oncol Biol Phys 1996; 70:273-80.
9. Grem JL. 5-Fluoropyrimidines In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy:Principles and Practice. 2nd Ed. Philadelphia, PA, USA: Lippencott, 1996:149-211.
10. Canman CE, Lawrence TS, Shewach DS, Tang HY, Maybaum J. Resistance to fluorodeoxyuridine - induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res 1993; 53:5219-24.
11. Grem JL, Mulcahy RT, Miller EM, Allegra CJ, Fischer PH. Interaction of deoxyuridine with fluorouracil and dipyridamole in human colon cancer cell line. Biochem Pharmacol 1989; 38:51-9.
12. Houghton JA, Tillman DM, Harwood FG. Ratio of 2′-deozyadenosine-5′-triphosphate /thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymidineless death. Clin Cancer Res 1995; 1:723-30.
13. Jones S, Willmore E, Durkacz BW. The effect of 5-fluoropyrimidines on nascent DNA synthesis in Chinese hamster ovary cells monitored by pH-step alkaline and neutral elution. Carcinogenesis 1994; 15:2435.
14. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5:2948-53.
15. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20:160-4.
16. Crane CH, EllisLM, Oreilly M, Ho L, Abbruzzese JL, Evans DB, et al. RhuMab VEGF (bevacizumab) with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer: An active, well tolerated regimen. Int J Radial Oncol Biol Phys 2004; 60(Suppl 1):S149.
17. Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase i/ii trial. J Clin Oncol 2003; 21:66-8.
18. Vaishampayan UN, Ben-Josef E, Philip PA, Vaitkevicius VK, Du W, Levin KJ, Shields AF. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys 2002; 53:675-9.
19. Reese T, Tanner J, Frings S, Dunst J. Capecitabine combined with simultaneous radiotherapy in rectal cancer: A phase I study (Abstr.). Int J Radiat Oncol Biol Phys 2000; 48:120-1.
20. Ngan S, Zalcberg J, Kell A, Michael M, MacKay J, Lim Joon, et al. A phase I study of capecitabine combined with radiotherapy locally advanced potentially operable rectal cancer (Abstract). Proc ASCO 2001; 20:591, 104a.
21. Yoon WH, Choi JH, Kim JR, Kim T, Lim K, Hwang B, et al. Enhanced tumoricidal effect of preoperative chemoradiation using capecitabine for locally advanced rectal cancer (Abstract). Proc ASCO 2001; 20:2165, 104b.
22. Ortmann E, Hohenberg G. Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine. J Clin Oncol 2002; 20:3029-30.
23. Jeffrey G, Truss C, Saif MW. Radiation recall syndrome associated with capecitabine. The Journal of Applied Research. 2004; 4:495-8.
24. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79:1516-20.
25. Brown MC. Multisite mucous membrane bleeding due to a possible interaction between warfarin and 5-fluorouracil. Pharmacotherapy 1997; 17:631-633.
26. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004; 91:673-7.
27. Pipas JM, Mitchell SE, Barth RJ Jr, Vera-Gimon R, Rathmann J, Meyer LP, et al. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2001; 50:1317-22.
28. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB 3rd. Eastern cooperative oncology group phase i trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000; 18:3384-9.